OA12227A - 5-AlkylpyridoÄ2,3-DÜpyrimidines tyrosine kinase inhibitors. - Google Patents

5-AlkylpyridoÄ2,3-DÜpyrimidines tyrosine kinase inhibitors. Download PDF

Info

Publication number
OA12227A
OA12227A OA1200200281A OA1200200281A OA12227A OA 12227 A OA12227 A OA 12227A OA 1200200281 A OA1200200281 A OA 1200200281A OA 1200200281 A OA1200200281 A OA 1200200281A OA 12227 A OA12227 A OA 12227A
Authority
OA
OAPI
Prior art keywords
compound
pyrido
methyl
pyrimidin
cyclopentyl
Prior art date
Application number
OA1200200281A
Other languages
English (en)
Inventor
Richard John Booth
Ellen Myra Dobrusin
Peter Laurence Toogood
Scott Norman Vanderwel
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of OA12227A publication Critical patent/OA12227A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
OA1200200281A 2000-03-06 2001-01-29 5-AlkylpyridoÄ2,3-DÜpyrimidines tyrosine kinase inhibitors. OA12227A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18712400P 2000-03-06 2000-03-06

Publications (1)

Publication Number Publication Date
OA12227A true OA12227A (en) 2004-03-18

Family

ID=22687699

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200200281A OA12227A (en) 2000-03-06 2001-01-29 5-AlkylpyridoÄ2,3-DÜpyrimidines tyrosine kinase inhibitors.

Country Status (36)

Country Link
EP (1) EP1268476A1 (fr)
JP (1) JP2003528101A (fr)
KR (1) KR20020075805A (fr)
CN (1) CN1422268A (fr)
AP (1) AP2002002643A0 (fr)
AR (1) AR034119A1 (fr)
AU (1) AU2001233028A1 (fr)
BG (1) BG107161A (fr)
BR (1) BR0109056A (fr)
CA (1) CA2401368A1 (fr)
CO (1) CO5280200A1 (fr)
CR (1) CR6736A (fr)
CZ (1) CZ20022929A3 (fr)
DZ (1) DZ3308A1 (fr)
EA (1) EA200200802A1 (fr)
EE (1) EE200200506A (fr)
GT (1) GT200100037A (fr)
HN (1) HN2001000040A (fr)
HR (1) HRP20020798A2 (fr)
HU (1) HUP0300136A2 (fr)
IL (1) IL151480A0 (fr)
IS (1) IS6524A (fr)
MA (1) MA26881A1 (fr)
MX (1) MXPA02008535A (fr)
NO (1) NO20024235L (fr)
NZ (1) NZ520962A (fr)
OA (1) OA12227A (fr)
PA (1) PA8513201A1 (fr)
PE (1) PE20011177A1 (fr)
PL (1) PL358271A1 (fr)
SK (1) SK12472002A3 (fr)
SV (1) SV2001000338A (fr)
TN (1) TNSN01036A1 (fr)
WO (1) WO2001070741A1 (fr)
YU (1) YU66502A (fr)
ZA (1) ZA200207110B (fr)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053070B2 (en) * 2000-01-25 2006-05-30 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
MXPA03003612A (es) 2000-10-23 2003-06-19 Smithkline Beecham Corp Compuestos novedosos.
KR100639772B1 (ko) * 2001-02-12 2006-10-30 에프. 호프만-라 로슈 아게 6-치환된 피리도-피리미딘
WO2002068419A1 (fr) 2001-02-26 2002-09-06 Tanabe Seiyaku Co., Ltd. Derive de pyridopyrimidine ou naphthyridine
US20030105115A1 (en) * 2001-06-21 2003-06-05 Metcalf Chester A. Novel pyridopyrimidines and uses thereof
US20030100572A1 (en) * 2001-06-21 2003-05-29 Ariad Pharmaceuticals,Inc. Novel pyridopyrimidones and uses thereof
GEP20063909B (en) 2002-01-22 2006-08-25 Warner Lambert Co 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d] PYRIMIDIN-7-ONES
CN1646131A (zh) 2002-04-19 2005-07-27 史密丝克莱恩比彻姆公司 新化合物
WO2004011456A1 (fr) 2002-07-31 2004-02-05 Danter Wayne R Inhibiteurs de proteine tyrosine kinase
US7629347B2 (en) 2002-10-09 2009-12-08 Critical Outcome Technologies, Inc. Protein tyrosine kinase inhibitors
BRPI0406809A (pt) * 2003-01-17 2005-12-27 Warner Lambert Co Heterociclos substituìdos de 2-aminopiridina como inibidores da proliferação celular
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
EP1663204B1 (fr) * 2003-08-29 2014-05-07 Exelixis, Inc. Modulateurs c-kit et leurs procedes d'utilisation
DK1685131T3 (da) 2003-11-13 2007-07-09 Hoffmann La Roche Hydroxyalkylsubstituerede pyrido-7-pyrimidin-7-oner
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004033670A1 (de) 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
FR2873118B1 (fr) 2004-07-15 2007-11-23 Sanofi Synthelabo Derives de pyrido-pyrimidine, leur application en therapeutique
US20060074088A1 (en) 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US7759485B2 (en) 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US7728134B2 (en) 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
EP1630163A1 (fr) 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinones, procédés de préparation et leur utilisation en tant que médicaments
CA2575804A1 (fr) * 2004-08-26 2006-03-02 Boehringer Ingelheim International Gmbh Pteridinones utilisees en tant qu'inhibiteurs des plk (polo-like-kinases)
DE102004058337A1 (de) 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
EP1856053A1 (fr) 2005-01-14 2007-11-21 Millennium Pharmaceuticals, Inc. Derives de cinnamide et d'hydrocinnamide presentant une activite inhibitrice de raf-kinase
EP1868612A4 (fr) 2005-03-25 2010-03-24 Glaxo Group Ltd Nouveaux composes
PE20061193A1 (es) 2005-03-25 2006-12-02 Glaxo Group Ltd DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2-[1H]-0NA COMO INHIBIDORES DE QUINASA p38
WO2006104917A2 (fr) 2005-03-25 2006-10-05 Glaxo Group Limited Procede de preparation de derives pyrido[2,3-d]pyrimidin-7-one et 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1h)-one
AR053346A1 (es) 2005-03-25 2007-05-02 Glaxo Group Ltd Compuesto derivado de 8h -pirido (2,3-d) pirimidin -7 ona 2,4,8- trisustituida composicion farmaceutica y uso para preparar una composicion para tratamiento y profilxis de una enfermedad mediada por la quinasa csbp/ rk/p38
US7737155B2 (en) * 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
FR2887882B1 (fr) 2005-07-01 2007-09-07 Sanofi Aventis Sa Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique
US7642270B2 (en) 2005-09-14 2010-01-05 Janssen Pharmaceutica N.V. 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase
TW200800983A (en) 2005-09-14 2008-01-01 Janssen Pharmaceutica Nv 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase
EP1931670B1 (fr) 2005-10-07 2012-09-12 Exelixis, Inc. Inhibiteurs pyridopyrimidinone de pi3k
EP2322523B1 (fr) * 2005-10-07 2019-01-02 Exelixis, Inc. Procédé de préparation d'inhibiteurs de PI3Kalpha de type pyridopyrimidinone
FR2896246B1 (fr) 2006-01-13 2008-08-15 Sanofi Aventis Sa Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
PL2074122T3 (pl) 2006-09-15 2011-10-31 Pfizer Prod Inc Związki pirydo(2,3-D)pirymidynonowe i ich zastosowanie jako inhibitory PI3
EP1914234A1 (fr) * 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines et leur utilisation comme inhibiteurs de kinases
BRPI0715566A2 (pt) * 2006-10-16 2013-07-02 Gpc Biotech Inc composto, prà-droga, composiÇço farmacÊutica, uso de um composto, mÉtodo para inibir a proliferaÇço de cÉlulas e mÉtodo para sintetizar um composto
WO2008055013A2 (fr) * 2006-10-31 2008-05-08 Janssen Pharmaceutica N.V. 5-oxo-5,8-dihydro-pyrido-pyrimidines comme inhibiteurs de la kinase c-fms
FR2910813B1 (fr) 2006-12-28 2009-02-06 Sanofi Aventis Sa Nouvelle utilisation therapeutique pour le traitement des leucemies
US8138181B2 (en) * 2007-04-03 2012-03-20 Array Biopharma Inc. Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors
RU2010101052A (ru) * 2007-06-15 2011-07-20 Банью Фармасьютикал Ко., Лтд (Jp) Производные бициклоанилина
EP2185559A1 (fr) 2007-08-03 2010-05-19 Boehringer Ingelheim International GmbH Forme cristalline d'un dérivé de dihydroptéridione
EP2231656A1 (fr) 2007-12-19 2010-09-29 Amgen Inc. Composés condensés de pyridine, de pyrimidine et de triazine en tant qu'inhibiteurs du cycle cellulaire
WO2009079797A1 (fr) 2007-12-26 2009-07-02 Critical Outcome Technologies, Inc. Composés et procédé pour le traitement du cancer
EP2100894A1 (fr) * 2008-03-12 2009-09-16 4Sc Ag Pyridopyrimidinones utilisés comme inhibiteurs de la kinase de type Plk1 (polo-like kinase)
CA2719538C (fr) 2008-04-07 2014-03-18 Amgen Inc. Pyridines/pyrimidines amino spirocycliques et disubstituees par gem en tant qu'inhibiteurs de cycle cellulaire
EP2112150B1 (fr) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Inhibiteurs Raf améliorés
WO2010006438A1 (fr) 2008-07-17 2010-01-21 Critical Outcome Technologies Inc. Composés inhibiteurs et procédés de traitement du cancer
UY32153A (es) 2008-09-30 2011-04-29 Exelixis Inc Inhibidores de piridomidinona de pi13ka(alfa) y mtor
TW201100441A (en) 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
EP2486037A4 (fr) * 2009-10-09 2013-01-16 Afraxis Inc 8-ethyl-6-(aryl)pyrido[2,3-d]pyrimidin-7(8h)-ones pour le traitement de troubles de snc
US8889696B2 (en) 2009-12-18 2014-11-18 Temple University—Of the Commonwealth System of Higher Education Substituted pyrido[2,3-d]pyrimidin-7(8H)-ones and therapeutic uses thereof
UY33221A (es) 2010-02-09 2011-09-30 Univ California MÉTODOS PARA TRATAR CÁNCER USANDO INHIBIDORES DE PI3K Y mTOR EN COMBINACIÓN CON INHIBIDORES DE AUTOFAGIA
US8987272B2 (en) 2010-04-01 2015-03-24 Critical Outcome Technologies Inc. Compounds and method for treatment of HIV
KR101434841B1 (ko) * 2010-08-05 2014-08-29 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 2-치환-8-알킬-7-옥소-7,8-디하이드로피리도[2,3-ｄ] 피리미딘-6-카르보니트릴 및 이의 용도
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
EP2646448B1 (fr) 2010-11-29 2017-08-30 OSI Pharmaceuticals, LLC Inhibiteurs de kinase macrocycliques
WO2012129344A1 (fr) 2011-03-23 2012-09-27 Amgen Inc. Doubles inhibiteurs tricycliques fusionnés de cdk 4/6 et de flt3
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
PT2710005T (pt) * 2011-05-17 2016-11-16 Principia Biopharma Inc Inibidores de tirosina-quinase
CN104271576A (zh) * 2012-02-23 2015-01-07 艾伯维公司 激酶的吡啶并嘧啶酮抑制剂
MX363715B (es) * 2013-02-21 2019-03-29 Pfizer Formas solidas de un inhbidor de cdk4/6 selectivo.
EP3024464A1 (fr) 2013-07-26 2016-06-01 Boehringer Ingelheim International GmbH Traitement du syndrome myélodysplasique
WO2016015597A1 (fr) * 2014-07-26 2016-02-04 Sunshine Lake Pharma Co., Ltd. Composés utilisés comme petits molécules inhibitrices de cdk et leurs utilisations
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
TWI646094B (zh) * 2016-06-01 2019-01-01 大陸商貝達藥業股份有限公司 Crystal form of inhibitory protein kinase active compound and application thereof
MA45920B1 (fr) 2016-08-15 2021-08-31 Pfizer Inhibiteurs de pyridopyrimidinone cdk2/4/6
KR102583737B1 (ko) * 2017-03-03 2023-09-26 오클랜드 유니서비시즈 리미티드 Fgfr 키나제 저해제 및 약학적 용도
BR112020015431A2 (pt) 2018-02-15 2020-12-08 Nuvation Bio Inc. Compostos heterocíclicos como inibidores de quinase
TW202035406A (zh) * 2018-12-07 2020-10-01 大陸商杭州英創醫藥科技有限公司 作為cdk-hdac雙通路抑制劑的雜環化合物
CN112759589B (zh) * 2019-11-01 2022-04-08 暨南大学 嘧啶并吡啶酮类化合物及其应用
US11697648B2 (en) 2019-11-26 2023-07-11 Theravance Biopharma R&D Ip, Llc Fused pyrimidine pyridinone compounds as JAK inhibitors
KR20230148235A (ko) * 2021-03-08 2023-10-24 지난 유니버시티 피리도피리미딘계 화합물 및 이의 응용
WO2024056091A1 (fr) * 2022-09-16 2024-03-21 华东师范大学 Dérivé de pyridonopyrimidine en tant qu'inhibiteur de rsk et son utilisation
WO2024099403A1 (fr) * 2022-11-10 2024-05-16 北京普祺医药科技股份有限公司 Composé thioéther ayant une propriété de médicament doux et son utilisation, composition pharmaceutique et utilisation associées
WO2024107730A1 (fr) * 2022-11-14 2024-05-23 Onconova Therapeutics, Inc. Méthodes et compositions pour le traitement du cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
EP0964864B1 (fr) * 1997-02-05 2008-04-09 Warner-Lambert Company LLC Pyrido 2,3d pyrimidines et 4-aminopyrimidines en tant qu'inhibiteurs de la proliferation cellulaire
ES2310039T3 (es) * 1998-05-26 2008-12-16 Warner-Lambert Company Llc Pirimidinas biciclicas y 3,4-dihidropirimidinas biciclicas como inhibidores de la proliferacion celular.

Also Published As

Publication number Publication date
SK12472002A3 (sk) 2003-04-01
HN2001000040A (es) 2001-09-06
PL358271A1 (en) 2004-08-09
CA2401368A1 (fr) 2001-09-27
WO2001070741A1 (fr) 2001-09-27
EA200200802A1 (ru) 2003-02-27
IL151480A0 (en) 2003-04-10
HUP0300136A2 (en) 2003-05-28
HRP20020798A2 (en) 2004-02-29
TNSN01036A1 (en) 2005-11-10
AR034119A1 (es) 2004-02-04
BG107161A (en) 2003-06-30
CR6736A (es) 2004-03-10
YU66502A (sh) 2005-09-19
NZ520962A (en) 2003-09-26
PE20011177A1 (es) 2001-11-23
KR20020075805A (ko) 2002-10-05
NO20024235D0 (no) 2002-09-05
MA26881A1 (fr) 2004-12-20
CO5280200A1 (es) 2003-05-30
ZA200207110B (en) 2003-12-04
JP2003528101A (ja) 2003-09-24
MXPA02008535A (es) 2002-12-13
CN1422268A (zh) 2003-06-04
IS6524A (is) 2002-08-23
CZ20022929A3 (cs) 2003-02-12
GT200100037A (es) 2002-03-04
EE200200506A (et) 2004-02-16
SV2001000338A (es) 2001-11-30
AP2002002643A0 (en) 2002-12-31
NO20024235L (no) 2002-11-05
AU2001233028A1 (en) 2001-10-03
PA8513201A1 (es) 2003-06-30
DZ3308A1 (fr) 2001-09-27
BR0109056A (pt) 2003-06-03
EP1268476A1 (fr) 2003-01-02

Similar Documents

Publication Publication Date Title
OA12227A (en) 5-AlkylpyridoÄ2,3-DÜpyrimidines tyrosine kinase inhibitors.
USRE47739E1 (en) 2-(pyridin-2-ylamino)-pyrido[2,3-D]pyrimidin-7-ones
US7326699B2 (en) 4-Amino-5-phenyl-7-cyclobutyl-pyrrolo(2,3-d)pyrimidine derivatives
CZ327597A3 (cs) Pyrido /2,3-d/ pyrimidiny pro inhibici protein tyrosin kinason zprostředkované buněčné proliferace
US7053070B2 (en) Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
OA12161A (en) PyridoÄ2,3-dÜpyrimidine-2,7-diamine kinase inhibitors.
EA005287B1 (ru) Птеридиноны в качестве ингибиторов киназ
MXPA04009058A (es) Derivados de 2,4-diaminopirimidina.
WO2008112695A2 (fr) Inhibiteurs de protéine kinase et procédés d'utilisation de ceux-ci
MXPA06007820A (es) Derivados de fenil-[4-(3-fenil-1h-pirazol-4-il)-pirimidin-2-il]-amina como inhibidores de igf-ir.
WO2005039486A2 (fr) Composes et compositions servant d'inhibiteurs de la proteine kinase
JP2012131795A (ja) 増殖性疾患の処置に有用なピロロピリミジン誘導体
MXPA06009158A (en) Compounds and compositions as protein kinase inhibitors